How to Move Smoothly and Quickly into Asian Markets

Biopharmaceutical Production How to Move Smoothly and Quickly into Asian Markets

2018-05-03 From Manja Wühr 5 min Reading Time

Related Vendors

Glatt Ingenieurtechnik GmbH

Catchay Communications

Italvacuum, Srl

TRM Filter d.o.o.

Biopharmaceutical companies looking to manufacture in the Middle East or India may find they can’t simply transfer the plant they’ve been using successfully in Europe, for logistic as well as regulatory reasons. An expert in integrated process technology and engineering, Glatt Ingenieurtechnik outlines the potential pitfalls and solutions.

Training staff early on helped Julphar Gulf Pharmaceuticals to achieve speedy commissioning and operation start at its new biotech plant in the UAE. (Source: Julphar) — Training staff early on helped Julphar Gulf Pharmaceuticals to achieve speedy commissioning and operation start at its new biotech plant in the UAE.
(Source: Julphar)

Transferring production of any pharmaceutical that contains biotechnologically produced active ingredients such as insulin, vaccines or antibodies using micro-organisms to a new country — especially one on a different continent — creates a number of challenges. Not only do technical documentation and technology have to be considered, but regulatory guidelines, which vary from country to country, and compliance issues must be addressed. The technology and engineering experts at German company Glatt Ingenieurtechnik know how to tackle these issues and have helped several companies to set up manufacturing facilities successfully and smoothly across the Middle East and India.

For many pharmaceutical projects, early availability is important and fast time-to-market are imperative for the manufacturer. Effective project management and scheduling are therefore crucial. Working to a clearly defined structure based on sound experience, when it receives an initial enquiry from a pharmaceutical manufacturer, Glatt asks two fundamental questions: Does a suitable biotechnological production process already exist within the company? Or will it need to be purchased from a technology provider or licensor? As soon as these points are clarified, the Glatt engineering team will begin to evaluate and compare the relevant technologies, in line with the pharma company’s specific criteria.

Please log in or register and read this article. To be able to read this article in full, you must be registered. Free registration gives you access to exclusive specialist information.

Create My Free Account

Already registered? Log in here

Subscribe to the newsletter now

Don't Miss out on Our Best Content

Business E-mail

Please enter a valid mailadress.

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Date: 08.12.2025

Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.